Welcome to our dedicated page for Exagen news (Ticker: XGN), a resource for investors and traders seeking the latest updates and insights on Exagen stock.
Exagen Inc. (Nasdaq: XGN) is a leader in autoimmune diagnostics, providing specialized testing solutions through its CLIA-certified laboratory and proprietary AVISE® platform. This page serves as the definitive source for verified news and announcements related to the company’s advancements in rheumatology diagnostics, financial developments, and strategic initiatives.
Investors and healthcare professionals will find timely updates on regulatory milestones, clinical study outcomes, and operational achievements. Our curated collection includes earnings reports, partnership announcements, and insights into biomarker research that drives Exagen’s industry-leading tests for conditions like lupus and rheumatoid arthritis.
All content undergoes rigorous verification to ensure alignment with financial disclosure standards and medical accuracy. Bookmark this page to efficiently track Exagen’s progress in improving diagnostic clarity for autoimmune diseases while staying informed about its role in advancing personalized medicine.
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, has scheduled its first quarter 2025 financial results announcement for May 5, 2025, before market opening. The company will host a conference call at 8:30 a.m. ET (5:30 a.m. PT) featuring President and CEO John Aballi and CFO Jeff Black.
Participants can join via phone at 201-389-0918 (U.S.) or +1-877-407-0890 (international), or through webcast available on the company's investor relations website. A replay will be accessible until May 19, 2025, through phone (201-612-7415 U.S., +1-877-660-6853 international, passcode 13753132) or webcast.
Exagen Inc. (XGN) reported strong financial results for Q4 and full-year 2024, achieving record total revenue of $55.6 million. The company demonstrated significant improvements in key metrics, including a 300 basis point increase in gross margin to 62.1% in Q4 and 59.5% for the full year.
The AVISE® CTD test reached a milestone of 1,000,000 patients tested, with its trailing twelve-month average selling price expanding to $411, a $75 increase per test. The company reduced its net loss by $1.8 million in Q4 and over $8 million for the full year compared to 2023.
Looking ahead, Exagen expects Q1 2025 revenue of at least $14.5 million and anticipates achieving positive adjusted EBITDA by Q4 2025. The company ended 2024 with $22.2 million in cash and restricted cash.
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, has scheduled the release of its fourth quarter and full-year 2024 financial results for March 11, 2025, before market opening. The company will host a conference call at 8:30 AM ET (5:30 AM PT) with President and CEO John Aballi and CFO Jeff Black to discuss the results.
Participants can join via phone at 201-389-0918 (U.S.) or +1-877-407-0890 (international), or through webcast available on the company's investor relations website. A replay will be accessible until April 14, 2025, at 11:59 PM ET through phone (201-612-7415 U.S., +1-877-660-6853 international, passcode 13751928) or webcast.
Exagen Inc. (Nasdaq: XGN), a leading autoimmune testing provider, has announced its participation in three upcoming investor conferences in early 2025:
1. BTIG at Snowbird Conference on February 11, 2025, at the Cliff Lodge in Snowbird, UT, featuring one-on-one investor meetings.
2. TD Cowen's 45th Annual Health Care Conference on March 5, 2025, at the Marriott Copley Place in Boston, MA, where President and CEO John Aballi and CFO Jeff Black will participate in a fireside chat at 1:10 p.m. EST, along with one-on-one investor meetings.
3. 5th Annual KeyBanc Capital Markets Healthcare Forum on March 18, 2025, featuring a virtual fireside chat and one-on-one investor meetings.
Investors can find more information and fireside chat links in the Events section of Exagen's website.
Exagen has received conditional approval from NY State for new lupus (SLE) and rheumatoid arthritis (RA) biomarker assays, planned for commercial launch in January 2025. The company announced preliminary unaudited financial results for Q4 and full year 2024, achieving:
- Record full-year revenue of $55.3-$55.8 million
- AVISE CTD trailing 12-month average selling price of $408-$412
- Net loss of ($14.8) to ($15.8) million
- Adjusted EBITDA of ($9.8) to ($10.8) million
- Cash position of $22.2 million
The new biomarkers include T-Cell Lupus profile (TC4d, TIgG, TIgM) for enhanced SLE diagnosis and RA profile with anti-RA33 biomarkers (IgA, IgG, IgM) for improved RA diagnosis. The company reached a milestone of testing its 1,000,000th patient with AVISE CTD and showed significant improvement in adjusted EBITDA by 37-43% compared to 2023.
Exagen Inc. has announced a significant milestone with the completion of its 1,000,000th AVISE CTD test, highlighting the test's widespread adoption in the rheumatologic community. The AVISE CTD test, launched in 2012, provides clinicians with important information for accurately diagnosing autoimmune and connective tissue diseases (CTD), offering superior accuracy compared to traditional screening methods.
The test's unique biomarkers enable confident and quick diagnosis of various CTDs, addressing the challenge of increasing autoimmune disease incidence. The milestone is supported by extensive peer-reviewed literature validating the test's clinical validity and utility in patient care.
Exagen has completed validation and submitted regulatory approval for new biomarkers to enhance its AVISE CTD platform, which aids in diagnosing autoimmune diseases. The enhancement includes seven new biomarkers: three T Cell biomarkers for improved Systemic Lupus Erythematosus (SLE) sensitivity, and four biomarkers for better rheumatoid arthritis (RA) diagnosis. AVISE CTD, operational since 2012, helps diagnose various connective tissue diseases where symptoms overlap, making differential diagnosis challenging. The platform's enhancement aims to provide clearer diagnostic information, potentially reducing repeat testing and improving patient outcomes.
Exagen Inc. (Nasdaq: XGN), a leading autoimmune testing solutions provider, has announced its participation in three major investor conferences. President and CEO John Aballi will present at the Canaccord Genuity MedTech Forum on November 21, 2024, at 3:00 p.m. EST in New York, the Evercore HEALTHCONx Conference on December 4, 2024, at 12:30 p.m. EST in Coral Gables, and will participate in a panel discussion titled 'Beyond Cancer' at the TD Cowen Diagnosing Tomorrow Conference on December 12, 2024, at 2:40 p.m. EST in New York. Management will also conduct one-on-one investor meetings at the first two events.
Exagen Inc. (Nasdaq: XGN), a leader in autoimmune testing solutions, reported financial results for Q3 2024. Revenue was $12.5 million, including a $1.2 million negative impact from one-time adjustments. The trailing twelve-month average selling price (ASP) for AVISE® CTD increased by 26% to $404. Gross margin was 55.8%, down from 57.4% in Q3 2023. Operating expenses decreased to $17.2 million from $18.5 million in Q3 2023. The net loss for the quarter was $5.0 million, an improvement from $5.4 million in Q3 2023.
For the first three quarters of 2024, revenue reached $42.0 million, up from $38.8 million in the same period of 2023. The net loss improved to $11.4 million, compared to $18.1 million in the first three quarters of 2023. Adjusted EBITDA loss also improved to $7.6 million from $13.2 million. Cash and cash equivalents were $22.0 million as of September 30, 2024. The company expects full-year 2024 revenue of $55-$56 million and an adjusted EBITDA loss of better than $12 million.
Exagen (Nasdaq: XGN), a provider of autoimmune testing, will release its third quarter 2024 financial results on November 12, 2024, before market opens. The company will host a conference call at 8:30 AM ET with President and CEO John Aballi and CFO Jeff Black. Investors can join via phone or webcast through the company's investor relations website. A replay will be available until November 26, 2024, through phone or webcast recording.
